ArticleThe oncologist2025
Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and RNA-based gene fusion analysis.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cancer genomic profiling has revolutionized cancer research and clinical practice by facilitating personalized medicine approaches. Next-generation sequencing technologies have played a pivotal role in expanding the possibilities of cancer genomics, providing a comprehensive view of the genomic landscape of tumors and identifying potential therapeutic targets. In Japan, the approval of several cancer-related gene panel tests has accelerated the implementation of cancer genomic medicine. However, there remains a need for evidence-based selection criteria for the different panel tests available. Among these tests, ACTOnco+® stands out as a comprehensive cancer genomic profiling tool. In this study, we compared 110 samples from 29 different tumor types using FoundationOne® CDx (324 genes for DNA analysis) and ACTOnco+® (440 genes for DNA and 31 genes for RNA analysis). Overall, the mutation profiles between the 2 assays exhibited 82.8% positive agreement in reported sequence alterations in clinically actionable genes, including single nucleotide variants and insertions-deletions. Copy number gains showed concordance of 76.9%, and copy number losses in 66.7%. In the case of KIAA1549-BRAF fusion-positive astrocytoma, the fusion event was not detected by DNA only test, but RNA sequencing identified the rearrangement. The patient exhibited clinical benefit from MEK inhibitor treatment. Tumor mutational burden and microsatellite instability (MSI) demonstrated high concordance across various cancer types. ACTOnco+® identified a total of 329 heterozygous deletions, which were subsequently validated for reliability using FISH analysis. Gene profiling with ACTOnco+® exhibited comparable results to FoundationOne® CDx, thereby contributing to future personalized medicine endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.